{"product_id":"reckitt-bcg-matrix","title":"Reckitt Benckiser Group Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eReckitt Benckiser’s product portfolio spans household staples to growing health and hygiene innovations, creating a mix of Cash Cows that fund R\u0026amp;D and potential Question Marks in emerging wellness categories—our BCG Matrix preview highlights competitive positioning and resource implications. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGaviscon Gastrointestinal Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGaviscon holds ~35% global market share in OTC antacids (2024 IMS Health), driven by aging populations and dietary shifts; category growth CAGR ~4.5% to 2025. The brand posts mid-single-digit net sales growth, aided by premium SKUs and Gaviscon Double Action launched 2023. Heavy clinical marketing and pharmacy channels keep it a Health unit star and primary organic growth engine by late 2025. Continued R\u0026amp;D spend (~£40–60m annually) is required to defend vs generics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNurofen Analgesics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNurofen is a global leader in OTC pain relief, holding ~12% global market share in analgesics in 2024 and driven by strong brand trust and R\u0026amp;D-led innovation.\u003c\/p\u003e\n\u003cp\u003eExpansion into higher-margin segments—long‑lasting patches and liquid softgels—lifted category revenues; patches grew 18% YoY in 2024, boosting margins by ~150 bps.\u003c\/p\u003e\n\u003cp\u003eBranded efficacy trends favor Nurofen: it gained share in developed and emerging markets, reaching estimated retail sales of £1.1bn in 2024.\u003c\/p\u003e\n\u003cp\u003eSustained marketing spend (~6% of sales in 2024) remains critical to defend versus private labels and aggressive pharma entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMucinex Respiratory Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMucinex Respiratory Solutions leads North America’s cough, cold, and flu market with ~18% category share in 2024 and frequent first-to-market multi-symptom SKUs, fueling rapid seasonal growth (Q4 sales +42% in 2024 vs. H1). \u003c\/p\u003e\n\u003cp\u003eThe brand expanded into nighttime and pediatric lines in 2022–24, keeping ASPs ~12% above category average while user base grew 9% YoY, classifying it as a BCG Star. \u003c\/p\u003e\n\u003cp\u003eReckitt spent roughly $220m on TV and $90m on digital in winter 2023–24 to sustain recall; if share gains persist, Mucinex can flip to a major cash generator as peak growth normalizes. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDurex Sexual Wellness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDurex Sexual Wellness is the market leader in sexual wellbeing, with global revenues around $1.1bn in 2024 and category growth of ~6–8% CAGR driven by health awareness and liberalization in Asia and LATAM.\u003c\/p\u003e\n\u003cp\u003eThe brand moved from condoms to a holistic offer—lubricants and sex-tech—segments growing double digits and raising margins versus basic protection.\u003c\/p\u003e\n\u003cp\u003eHuge global footprint but needs heavy local marketing and social-media spend to win Gen Z; Reckitt invested ~£120m in brand \u0026amp; digital in 2023–24.\u003c\/p\u003e\n\u003cp\u003eStrong positions in Asia and Europe make Durex a cash-generating, strategic BCG asset with upside if localized investments scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~$1.1bn\u003c\/li\u003e\n\u003cli\u003eCategory growth ~6–8% CAGR\u003c\/li\u003e\n\u003cli\u003eLubricants\/sex-tech: double-digit growth\u003c\/li\u003e\n\u003cli\u003e£120m brand\/digital spend 2023–24\u003c\/li\u003e\n\u003cli\u003eMarket dominance: Asia, Europe\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrepsils Medicated Confectionary\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrepsils Medicated Confectionary sits as a Cash Cow in Reckitt Benckiser’s BCG matrix: it leads the global medicated sore-throat category with ~22% market share in 2024 and grew revenues ~8% YoY, driven by post‑pandemic self‑care trends and strong pharmacy placement.\u003c\/p\u003e\n\u003cp\u003eNew sugar‑free and herbal variants lifted volume by ~12% in 2024, attracting health‑conscious buyers, while pharmacy channel fill rates above 90% create a durable moat against new entrants; ongoing promo spend (estimated £40–50m annually) is needed to defend position as the category expands ~4–5% CAGR to 2027.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 market share ~22%\u003c\/li\u003e\n\u003cli\u003eRevenue growth ~8% YoY\u003c\/li\u003e\n\u003cli\u003eVariant-driven volume +12% in 2024\u003c\/li\u003e\n\u003cli\u003ePharmacy fill \u0026gt;90%\u003c\/li\u003e\n\u003cli\u003ePromo spend est £40–50m\/yr\u003c\/li\u003e\n\u003cli\u003eCategory CAGR ~4–5% to 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTop OTC Stars 2024: Gaviscon, Nurofen, Mucinex, Durex—High Share, Big Investment Needed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Gaviscon, Nurofen, Mucinex, Durex—high share, high growth; 2024 sales: Gaviscon ≈£650m (35% antacids), Nurofen £1.1bn (12% analgesics), Mucinex US share 18%, Durex £1.1bn (global). Key spends: R\u0026amp;D £40–60m\/yr (Gaviscon), marketing £220m TV\/£90m digital (Mucinex), brand £120m (Durex). Continued investment needed to sustain share gains.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eKey spend\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGaviscon\u003c\/td\u003e\n\u003ctd\u003e£650m\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D £40–60m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNurofen\u003c\/td\u003e\n\u003ctd\u003e£1.1bn\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003ctd\u003eMarketing 6% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMucinex\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e18% US\u003c\/td\u003e\n\u003ctd\u003e£310m winter spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDurex\u003c\/td\u003e\n\u003ctd\u003e£1.1bn\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e£120m brand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix for Reckitt: strategic placement of brands into Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Reckitt Benckiser units in quadrants for quick strategic clarity and prioritization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDettol Hygiene Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDettol Hygiene Solutions dominates antiseptic and hygiene markets in Europe, Asia and Africa with estimated 2024 retail market share ~35% in India, ~40% in UK personal antiseptics and strong presence across Africa; annual sales for Dettol-brand items were roughly £1.2bn in 2024 within Reckitt’s hygiene portfolio.\u003c\/p\u003e\n\u003cp\u003eAfter pandemic-driven spikes in 2020–21, growth normalized to low single digits by 2023–24, producing stable, predictable cash flows and gross margins near Reckitt’s hygiene segment average (~58% in 2024).\u003c\/p\u003e\n\u003cp\u003eDettol needs modest capex and marketing versus Stars, freeing about £250–350m annual operating cash for Reckitt to reallocate to R\u0026amp;D and acquisitions (2024 free cash flow context).\u003c\/p\u003e\n\u003cp\u003eHigh-volume, staple sales support dividends and debt servicing; Reckitt’s 2024 net leverage fell to ~2.6x after using Dettol cash to reduce net debt and pay a £1.05 per-share FY 2024 dividend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLysol Disinfectant Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLysol dominates North America with roughly 40–45% market share in household disinfectants (2024 IRI data), holding stable in a mature market where usage is habitual.\u003c\/p\u003e\n\u003cp\u003ePost-pandemic growth slowed to low-single digits annually, but gross margins remain high—Reckitt reported ~28% gross margin on Home Care in FY2024—driven by scale and a lean supply chain.\u003c\/p\u003e\n\u003cp\u003eMarketing now targets maintenance and small-product innovations (scent, formats) rather than share grabs, keeping A\u0026amp;P spend steady at ~6% of sales.\u003c\/p\u003e\n\u003cp\u003eConsistent cash flow funds Reckitt’s shift to high-growth health platforms, contributing a multi-hundred-million-dollar free cash flow buffer in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinish Dishwashing Detergents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFinish is the global leader in automatic dishwashing, holding ~25% global market share in 2024 and growing unit volumes in emerging markets as dishwasher penetration rises from 18% to 26% in APAC (2020–2024).\u003c\/p\u003e\n\u003cp\u003eThe category shows low single-digit growth (~2–3% CAGR), but Finish sustains high margins via premium Quantum and Powerball lines, with gross margins around 45% in 2024.\u003c\/p\u003e\n\u003cp\u003eRequired capex is minimal—maintenance of supply and marketing—so Finish generates strong free cash flow, often redirected to Reckitt R\u0026amp;D for hygiene and health, which rose to £350m in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarpic Lavatory Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHarpic dominates the specialized toilet-cleaner segment in key markets like India, holding roughly 60–70% market share as of 2025 and remaining the category benchmark.\u003c\/p\u003e\n\u003cp\u003eCategory growth has stabilized to mid-single digits, but Harpic’s high market share and low reinvestment needs generate steady cash flow—Reckitt reported household-care margins supported by Harpic in FY2024.\u003c\/p\u003e\n\u003cp\u003eHigh entry barriers—deep distribution, brand trust, and SKU scale—mean only tactical promos are needed to defend share, making Harpic a classic cash cow for Reckitt.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60–70% market share in India (2025)\u003c\/li\u003e\n\u003cli\u003eCategory growth: mid-single digits\u003c\/li\u003e\n\u003cli\u003eLow reinvestment, steady free cash flow\u003c\/li\u003e\n\u003cli\u003eHigh entry barriers: distribution + trust\u003c\/li\u003e\n\u003cli\u003eDefence via tactical promotions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVanish Fabric Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVanish is the global market leader in fabric additives and stain removal, with ~35% category share and stable household penetration above 70% in key markets as of 2025; the segment is mature, growing ~1–2% annually, so volume upside is limited.\u003c\/p\u003e\n\u003cp\u003eThe brand delivers high gross margins (~45% reported in Reckitt 2024 segment disclosures) and strong loyalty—repeat purchase rates exceed 60%—so Reckitt extracts cash via price mix and cost savings.\u003c\/p\u003e\n\u003cp\u003eReckitt prioritizes operational efficiencies and supply-chain savings to maximize free cash flow from Vanish, which underpinned ~8% of Reckitt Group operating cash flow in FY 2024, providing stability against volatility in other units.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share ~35%\u003c\/li\u003e\n\u003cli\u003eCategory growth 1–2%\/yr\u003c\/li\u003e\n\u003cli\u003eGross margin ~45%\u003c\/li\u003e\n\u003cli\u003eRepeat purchase \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003eContributed ~8% of FY24 operating cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReckitt’s cash cows—Dettol, Lysol, Finish, Harpic, Vanish fuelling 2024 FCF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDettol, Lysol, Finish, Harpic and Vanish are Reckitt cash cows: high market shares (Dettol ~35% India, Lysol 40–45% US, Finish ~25% global, Harpic 60–70% India, Vanish ~35%) with low single-digit growth, high gross margins (hygiene ~58%, Home Care ~28%, Finish\/Vanish ~45%) and strong 2024 free cash flow supporting dividends, debt paydown and R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eGross margin\u003c\/th\u003e\n\u003cth\u003e2024 cash role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDettol\u003c\/td\u003e\n\u003ctd\u003e~35% India\u003c\/td\u003e\n\u003ctd\u003elow 1–3% \u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003ctd\u003e£250–350m op cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLysol\u003c\/td\u003e\n\u003ctd\u003e40–45% US\u003c\/td\u003e\n\u003ctd\u003elow 1–3%\u003c\/td\u003e\n\u003ctd\u003e~28% (Home Care)\u003c\/td\u003e\n\u003ctd\u003estable cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinish\u003c\/td\u003e\n\u003ctd\u003e~25% global\u003c\/td\u003e\n\u003ctd\u003e2–3% CAGR\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003ctd\u003estrong FCF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHarpic\u003c\/td\u003e\n\u003ctd\u003e60–70% India\u003c\/td\u003e\n\u003ctd\u003emid-single digits\u003c\/td\u003e\n\u003ctd\u003ehousehold-care avg\u003c\/td\u003e\n\u003ctd\u003elow reinvestment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVanish\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003e1–2% \u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003ctd\u003e~8% of FY24 op cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eReckitt Benckiser Group BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Reckitt Benckiser Group BCG Matrix report you'll receive after purchase—no watermarks or demo indicators, just a fully formatted, analysis-ready document crafted for strategic clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748092391801,"sku":"reckitt-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/reckitt-bcg-matrix.png?v=1772204675","url":"https:\/\/matrixbcg.com\/products\/reckitt-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}